China (Mainland)
Diamondsupplier 
- Product Details
Keywords
- SUNITINIB MALATE
- N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate
- (Z)-N-(2-(diethylaMino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)Methyl)-2,4-diMethyl-1H-pyrrole-3-carboxaMide (S)-2-hydroxysuccinate
Quick Details
- ProName: SUNITINIB MALATE
- CasNo: 341031-54-7
- Molecular Formula: C22H27FN4O2.C4H6O5
- Appearance: Pale yellow to off-white powder
- Application: A multi-kinase inhibitor targeting sev...
- DeliveryTime: 3-5 days
- PackAge: as your request
- Port: Tianjin
- ProductionCapacity: 10 Metric Ton/Month
- Purity: 99%
- LimitNum: 100 Gram
Superiority
|
Item |
Specification |
Results |
|
Appearance |
Pale yellow to off-white powder |
Conforms |
|
Identification |
a) IR:IR chromatograph Conforms to the characteristic peak of R.S. |
Conforms |
|
b) HPLC :The retention time of the major peak in the chromatogram Conforms to the characteristic peak of R.S. |
Conforms |
|
|
Residue on ignition |
≤ 0.1% |
0.07% |
|
Loss on drying |
≤1.0% |
0.35% |
|
Heavy Metals |
≤20 ppm |
Conforms |
|
Related substance |
||
|
Single impurity |
≤0.50% |
0.22% |
|
Total impurities |
≤1.0% |
0.61% |
|
Assay[HPLC] |
≥99.0% |
99.53% |
|
Conclusion |
The results comply with standards of enterprise. |
|
Details
Sunitinib malate is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor. Sunitinib malate was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) on January 26, 2006. Sunitinib malate was the first cancer drug simultaneously approved for two different indications.